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Objective. Overall, the literature on the effectiveness of psychological treatments in general and those for fibromyalgia in particular
has been dominated by research designs that focus on large groups and explore changes on average, so the treatment impact at the
individual level remains unclear. In this quasi-experimental, replicated single-case design, we will test the feasibility and ef-
fectiveness of a brief acceptance and committed therapy intervention using ecological momentary assessment supported by
technology.Methods.,e sample comprised 7 patients (3 in the individual condition and 4 in the group condition) who received a
brief, 5-week psychological treatment. Patient evolution was assessed one week prior to treatment onset and during the whole
study with a smartphone app. Because ecological momentary assessment and the use of an app are not frequent practices in
routine care, we also evaluated the feasibility of this assessment methodology (i.e., compliance with the app). Change was
investigated with a nonoverlap of all pairs index. Outcomes were pain interference with sleep and social activities, fatigue, sadness,
and pain intensity. Results. Patient change was not uniform across outcomes. Four patients (two in each condition) showed
relatively moderate levels of change (approximately 60% nonoverlap in several outcomes). ,e remaining patients showed more
modest improvements which affected a reduced number of outcomes. Based on nonoverlapping indices, there was no clear
evidence in favor of any treatment format. Conclusions. An alternative design to large-scale trials, one that focuses on the
individual change, exists and it can be implemented in pain research. ,e use of technology (e.g., smartphones) simplifies such
designs by facilitating ecological momentary assessment. Based on our findings showing that changes were not homogeneous
across patients or outcomes, more single-case designs and patient-centered analyses (e.g., responder and moderation analyses)
are required.
1. Introduction
Fibromyalgia (FM) is a rheumatic disease characterized by a
history of widespread musculoskeletal chronic pain, sleep
disturbance, debilitating fatigue, joint stiffness, and cognitive
(memory, attention, perception, coordination) dysfunction
and is frequently associated with depression and anxiety-
related disorders [1–3]. FM is a very prevalent disease
worldwide, with estimates suggesting that between 2% and
5% of individuals, mostly females, experience this syndrome
globally [4, 5].
,ere is now quality evidence supporting the utility of
several pharmacological (i.e., antidepressants and antisei-
zure drugs) and nonpharmacological treatment (i.e., Cog-
nitive Behavioral ,erapy, CBT) options for FM [6, 7].
Indeed, CBT has become a frequent treatment for FM pa-
tients, and systematic reviews and meta-analyses so far
indicate that moderate effects on physical disability and
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mental distress are obtained with CBT, while pain intensity
changes tend to be smaller [8, 9].
While these results with CBT are encouraging, the past
years have evidenced an increasing interest in the so-called
“third wave” psychological interventions for pain manage-
ment, such as Acceptance and Commitment,erapy (ACT).
Different from CBT, ACT does not aim at reducing or
modifying distressing pain-related thoughts, emotions,
sensations, or memories but promotes the psychological
acceptance of suffering as a way of reaching personal values
[10, 11]. Some authors have proposed that, due to the dif-
ficulties in controlling pain in chronic pain populations,
including FM patients (e.g., note that the poorer effects of
CBT on outcomes appear when attempting to reduce pain
levels), ACTmight better adjust to the needs of these patients
because the goal lies in accepting suffering (i.e., pain), as
opposed to trying to control it, in the process of leading a
value-driven life [12, 13].
So far, the results on the effectiveness of ACT for FM are
encouraging [14]. However, the results about the effec-
tiveness of ACT in FM are mostly based on group studies
with a limited number of assessments (i.e., pretreatment,
posttreatment, and follow-upmeasures) [15, 16].,is means
that there are important questions that remain unexplored.
For instance, it is unclear whether a group format is more
effective than an individual one for this population.
Moreover, while the use of large samples and average
change-scores in randomized controlled trials is a frequent
practice in clinical research, these designs only show changes
on average, so the effectiveness of ACT for FM at the in-
dividual level is yet unclear (i.e., for how many patients
treatment works and to what extent). Additionally, these
designs require the existence of a control group, which is
ethically problematic. ,ere is indeed a growing call for
studies using research designs that overcome these limita-
tions [17]. It has been argued that single-case designs (SCDs)
are the preferred alternatives to large-scale randomized
controlled trials, both in clinical research in general [18] and
in chronic pain in particular [19, 20], due to their focus on
the individual and the fact that no control group is required
(patient baseline is used as the control condition).
In light of the previous limitations, in the present study
we will compare the effectiveness of a brief ACT intervention
for patients participating in a group or an individual
treatment using a SCD. Contrary to the traditional episodic
assessment of randomized clinical trials and in accordance
with requirement for SCDs, assessment will be ecological
and momentary using a smartphone app developed and
validated by our team [21]. Treatment effectiveness will be
investigated at the individual level. Based on previous re-
search comparing group and individual CBT treatment in
other populations [22], we expect to obtain similar effects in
both formats as revealed by a reduction of pain interference
in sleep and social activities, fatigue, and sadness. A re-
duction in pain intensity as a secondary gain of the inter-
vention is also anticipated, but not primarily targeted. As
recommended, the analyses of treatment effectiveness will
not be explored visually, but using nonoverlap indices (i.e.,
nonoverlap of all pairs) [23, 24]. We expect to find similar
nonoverlap indices (medium for pain interference with sleep
and social activities, fatigue, and sadness and small for pain
intensity) across patients, based on the assumption that
group-level changes in past research are indicative of a
similar improvement across individuals. ,ese nonoverlap
indices have become a recommended practice in SCDs as an
alternative to visual analysis only as they allow obtaining
more objective evidence of change by comparing the patient
responses in the baseline against the scoring in the treatment
phase [25].
2. Method
2.1. Design. A single-case AB (A: baseline; B: treatment)
design was implemented. In psychological treatments de-
signs, ABAB is not usually recommended, as it is not very
usual that individuals return to baseline levels (A) after
treatment (B) [26, 27]. Additionally, more robust designs,
such as a multiple-baseline design, were not implemented
here because they are difficult to use in group therapy (i.e.,
they require a stepped inclusion of the individuals in dif-
ferent sessions of the treatment) [28]. ,erefore, while AB is
a frequent SCD [29], it should be considered a quasi-ex-
perimental design. ,erefore, causal inferences cannot be
unequivocally made from the findings.
2.2. Procedures. Participants were recruited at the Fibro-
myalgia Association of Burriana and were treated at our
University Psychological Assistance Service. Patients had
been previously diagnosed with FM by a rheumatologist.,e
participants were randomly allocated to one of two condi-
tions, (1) group therapy and (2) individual therapy, by an
independent researcher using a randomization tool (http://
www.randomizer.org). All participants gave their written
consent to participate prior to randomization. An ap-
pointment was set one week before treatment onset to help
participants download and make a first use of the app. ,is
daily assessment during the week prior to treatment was
used as baseline measurement. Participants continued using
the app during the whole treatment (B). ,e study and
assessment ended a week after the last treatment session (5
weeks after treatment onset).
Ecological momentary assessment was performed on a
daily basis (twice a day, in the morning and in the evening, at
preset times) with Pain Monitor, an app developed and
validated by our team for chronic pain patients [21].,e app
was used for 6 weeks (one week prior to treatment and five
weeks during the treatment). ,erefore, as recommended in
the guidelines, at least five observations were obtained for
each phase [17].
,e study was approved by the Ethics Committee of the
Jaume I University on June 24, 2018.
2.3. Sample. In SCDs, only 1 participant is required for the
analyses. However, more participants are recommended for
replication of effects and to facilitate the generalization of
findings [17]. ,erefore, we approached 13 patients at a FM
association in Burriana (Spain), of which 10 agreed to
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participate, met the eligibility criteria, and provided written
consent to participate. ,e resulting number of participants
was 10 (5 for each condition). However, one participant
from the group therapy did not receive treatment due to an
unexpected surgical intervention happening just before
treatment onset. Additionally, two patients in the individual
therapy condition could not participate due to family
problems that required their presence at home. ,erefore,
the final number of participants was 7 (4 in the group
condition and 3 in the individual one).
,e eligibility criteria included the following:
(a) ,e patient is over 18 years of age.
(b) ,e patient does not present with psychological and/
or cognitive alterations or problems with language
that make their participation difficult.
(c) ,e patient has the physical ability to use the
application.
(d) ,e patient voluntarily wants to participate and signs
the informed consent form.
(e) ,e patient has a mobile phone with an Android
operating system.
In terms of eligibility, it is important to note that past
research has indicated that the use of technology is often
more problematic in the elderly [30]. ,is could lead us to
think of old age as a potential exclusion criterion. However,
our team has a long experience designing technologies for
the elderly, and the application used in the present inves-
tigation has been successfully implemented in previous
research with older patients with chronic pain [21].
,erefore, participation in the present study was not re-
stricted to younger individuals despite the inclusion of a
smartphone application for assessment, and participants
were only deemed ineligible if they had physical problems
that would prevent them from using the application.
2.4. Treatment Plan. ,e treatment program is a brief ACT
protocol based on an ACT treatment created by our group,
LabPsiTec, which has been used for FM in a group format in
primary care settings [31]. Both treatments followed the
same protocol and were delivered by the same psychologist,
MC, who is experienced in the use of ACT in patients with
FM. ,e use of such brief ACT interventions is becoming a
frequent and recommended practice in clinical settings [32]
and might be especially suitable for FM patients due to a
frequent dropout rate and difficulties in attending treatment
in this population, frequently as a consequence of their
health status [15, 33].
,e treatment included 5 weekly sessions. Each session
was 1 hour long for the individual therapy and had a du-
ration of 1 and a half hours for the group condition. Group
therapies require a longer extension as the participants need
more time to interact with each other [34].
As noted before, the number of sessions was reduced to
obtain a brief version that includes the key aspects of ACT
(i.e., psychological flexibility, acceptance of pain, cognitive
defusion, values, mindfulness, and committed action)
because long treatments have shown high dropout rates due
to time constraints in this type of patients, which would be
problematic in a single-case design.
Treatment started on 26/04/2018 and had a duration of
5 weeks.,e treatment components are described in Table 1.
2.5. Measures
2.5.1. Pain Monitor App. ,e application used in this study,




,e content in the app was developed by a multidisci-
plinary team of psychologists, physicians, and nurses from
the Pain Clinic of the Vall d’Hebron Hospital and the
LabPsiTec group of the Jaume I University. All items in the
app have been adapted from well-established measures, and
the complete protocol to be used in an app and EMA format
has been recently validated in a chronic pain population [21].
,e app uses a push system to inform the patient when to
respond. Assessments occur twice a day, in the morning and
the evening (10 am and 7 pm, with a two-hour flexibility).
Study outcomes included pain interference with sleep and
social activities, fatigue, and sadness (primary outcomes), as
well as pain intensity (secondary outcome). ,e items used
to measure the study outcomes are described in Appendix
A.,e focus on outcomes beyond pain intensity is consistent
with modern perspectives on chronic pain management
[35]. Most constructs in the app are assessed twice a day (e.g.,
because sadness can vary from morning to evening, this was
evaluated at both times). However, pain interference was
evaluated once a day only due to its content (e.g., because all
participants slept at night, interference with sleep was
evaluated in the morning only, while interference with social
activities was assessed in the evening only). All items have
been adapted from and validated against traditional, well-
established scales in a previous study [21]. A reduced
number of items is fundamental in ecological momentary
assessment [36].
2.6. Calculations and Analyses. Traditionally, visual analysis
of the data has been used as an indicator of performance in
single-case research, by observing differences between the
baseline (A) and the intervention (B) phases. However,
visual analysis shows many limitations, including type 1 and
2 errors and poor interrater reliability [17]. Nonoverlap
indices, specially the nonoverlap of all pairs (NAP) which is
the more robust to bias, can solve some of the problems of
visual analysis by offering a mathematical calculation of the
overlap between A and B phases [24].
Different from other overlap indices, NAP accounts for
all data overlap between each phase A data point and each
phase B measurement [37]. NAP can be relatively easily
calculated by dividing the number of nonoverlapping
comparisons (between each A and B point) by the total
number of possible comparisons. ,erefore, NAP calculates
the percentage of data that shows an improvement
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(functional outcomes) or a deterioration (dysfunctional
outcomes) with respect to the baseline. In order to interpret
the NAP values, the median nonoverlap of treatment studies
has been proposed [38]. A nonoverlap below 38% corre-
sponds to the 25th percentile of lowest reported NAP scores
across studies, so this should be interpreted as a poor
treatment effect. A NAP between 38% and 68% would in-
clude studies between the 25th and 50th percentile of pub-
lished effects, which might be interpreted as representing a
mild-to-moderate intervention effect. A moderate-to-large
effect would be represented by nonoverlap indices between
69% and 96% (median nonoverlap effects of studies between
the 50th and the 75th percentile). Finally, NAP scores over
96% correspond to very large treatment effects (median
effects of studies above the 75th percentile of published ef-
fects). Overlap indices are calculated using within-person
data and compare the baseline to all data points obtained
during the entire treatment period.
Compliance with the app was explored both for morning
and evening assessments and was calculated by dividing the
number of reported responses by the number of possible
assessments.
3. Results
Patient demographic characteristics, as well as their non-
overlap calculations, and app compliance rates are reported
in Table 2.
3.1. Participants. All participants were women. ,eir age
ranged between 53 and 67 years, and all of them had been
suffering FM symptoms for more than 5 years. Educational
level was low in most participants (primary or secondary
education only, with the exception of a patient who had
completed technical studies), and they were not very familiar
with the use of smartphones applications. One woman was a
widow, while the remaining participants were married.
3.2.NonoverlapAnalyses. Regarding interference with sleep,
three patients (patients 1 and 2 from the group condition
and patient 7 who followed an individual intervention)
showed very poor improvement (less than 10% of non-
overlap). ,eir average baseline interference of pain with
sleep was 8.8, 4.2, and 3.2, respectively. ,e remaining
participants showed an improvement that corresponds to
the 25th-50th percentile range of existing effects in AB SCDs
(i.e., between 48% and 60% of nonoverlap in our sample),
which should be interpreted as mild-to-moderate effects
[38]. ,eir average baseline interference of pain with sleep
ranged from 3.2 to 5.6.
Different from interference with sleep, interference of
pain with social functioning was more satisfactorily im-
proved in the sample. Specifically, three patients (patient 2 in
the group condition and patients 5 and 6 in the individual
treatment condition) showed an improvement which is close
to the 50th percentile of existing effects in AB SCDs (i.e.,
between 60% and 62% of nonoverlap), which should be
interpreted as a moderate effect. ,eir average baseline
interference of pain with social functioning was 4.8, 1.4, and
2.0, respectively. Additionally, the remaining patients
showed larger improvements compared to interference with
sleep (i.e., between 22% and 35% nonoverlap). ,eir average
baseline interference of pain with social functioning ranged
from 3.6 to 5.0.
Regarding fatigue, only two patients in the group con-
dition obtained nonoverlap scores that would correspond to
less than the 25th percentile of existing effects in AB SCDs.
Baseline average fatigue levels of the two individuals were 6.7
and 6.2. ,e remaining patients showed improvements that
would be between the 25th and the 50th percentile of the
aforementioned effects (i.e., NAP between 41% and 53%),
that is, changes that correspond to mild-to-moderate effects.
,eir average baseline fatigue levels ranged from 4.3 to 6.7.
In a similar way to fatigue, three patients (two in the
group condition and one in the individual treatment con-
dition) showed poor improvement in sadness (i.e., scores
below the 25th percentile). ,ese patients had baseline
sadness scores ranging from 4.33 to 5.57. ,e remaining
patients showed larger improvements than those for fatigue
(i.e., NAP between 53% and 64%), which would again
correspond to NAP values between the 25th and the 50th
Table 1: Psychological components of the program.
Session Component Goal
1
Psychoeducation Brief description of the most prominent symptoms of FM and their interference in the daily activities andemotional functioning. In the group condition, it also included rules and structure
Motivation for
change Motivation for changing our behavior patterns
2
Acceptance Learning to be in contact with internal bodily sensations (i.e., pain), even if they are unpleasant.
Willingness to accept them as they are in the way of achieving a more meaningful lifeMindfulness
Cognitive defusion Experiencing sensations as they are and not the way the mind says they are
Self as observer Identification of the observer self
3 Values Clarification of personal, professional, and health-related valuesCommitted action Taking value-driven actions
4 Compassion Learning self-care techniques (compassion)
5 Relapse prevention Revision of acquired abilitiesAnticipation of future difficulties and barriers and detection of skills to be used in such scenarios
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percentile of existing effects in AB SCDs. ,eir average
baseline sadness scores had a 2.78–6.89 range.
Finally, improvement in pain levels was poor (i.e., below
the 25th percentile of existing effects in AB SCDs) for most
patients (i.e., four). ,eir average baseline pain levels ranged
from 5.9 to 6.9. ,ree patients showed a NAP between 47%
and 55%, which would correspond to NAP values between
the 25th and the 50th percentile of existing effects in AB
SCDs. ,eir average baseline pain levels were 3.7 (patient 6),
5.6 (patient 5), and 6.3 (patient 7).
Figures 1 and 2 show a graphical representation of a very
poor and a modest response to treatment, respectively.
3.3. Feasibility of EMAUsing anApp. All patients reported at
least five responses in each phase (baseline and treatment).
At the group level, evening compliance with the app was
68.37% (participants provided 195 responses out of 294
requested measurements). Morning compliance with the
app was 61.22% (participants provided 180 responses out of
294 requested measurements). As reported in Table 2, at the
patient level, response rates ranged from 45.2% to 88.10%.
Only one patient reported response rates below 50%, and
this was due to technical problems with the phone (low
memory capacity) that blocked the push system that reminds
the patient to respond to the app. When this was identified
(an alarm that reached the researchers was set to identify
when a patient failed to respond to three consecutive as-
sessments), we addressed this by encouraging the patient to
respond to the app even in the absence of notifications, but
this made compliance more difficult.
4. Discussion
,e literature on clinical research in general and chronic
pain in particular has been largely dominated by large-scale
randomized clinical trials in which the analysis of changes,
mostly with group interventions, is explored considering
average group scores and a reduced number of assessments
[39, 40]. While large-scale randomized clinical trials are
clearly informative and can address very important ques-
tions including responder and moderation analyses, the
overrepresentation of this type of studies in the literature can
also be problematic for a number of reasons. First, because
such designs mostly focus on average population treatments
effects [41, 42]. Additionally, an alternative to large-scale
trials is required for studies addressing the development of
new treatments and the intervention with infrequent dis-
orders, to test the efficacy of an intervention in routine
practice with a reduced number of individuals. ,is study
contributes to the existent literature in this direction by
testing the effectiveness of a brief psychological treatment for
chronic pain in routine care. First, it focused on changes at
the individual level by implementing a single-case design.
Additionally, it implemented a brief ACT treatment, which
might bemore feasible for FM patients in terms of adherence
due to its short duration, and explored changes using a
modern analytic strategy (i.e., nonoverlap of all pairs) which
minimizes the reliability problems of visual analysis. Finally,
the present investigation evaluated all outcomes ecologically
and repeatedly (i.e., daily) using a modern approach, that is,
a validated smartphone app. ,us, the present investigation
might help inspire and serve as a guide for future investi-
gations in pain research.
One of the findings in the present investigation was that
not all patients improved to the same extent after treatment
onset. Also interestingly, changes were not homogeneous
across outcomes. For example, patients 5 and 6 showed
relatively similar levels of change in all study outcomes. On
the contrary, the majority of patients showed some change in
a number of outcomes (e.g., patient 2 in social interference,
patient 3 in sadness, and patient 7 in pain intensity) and
barely no change in others (e.g., patient 2 in interference
with sleep, fatigue, sadness, and pain intensity and patient 7
in sleep interference and sadness). As recommended in
recent clinical research including the pain literature [27, 43],
these findings suggest that aggregating data is indeed likely
to mask a lack of response of an important number of in-
dividuals in some outcomes by including larger changes by
other individuals in such variables. As notedmany years ago,
while managers and trialists might be happy when treat-
ments work on average, patients surely expect clinicians to
do better than that [44]. ,e present investigation is a step
forward in this direction.
Another interesting result was that, based on the NAP
indices, there was no clear evidence in favor of any of the two
treatment conditions (group or individual intervention).
,is is consistent with our hypothesis based on a previous
meta-analysis [22]. Some positive benefits have been tra-
ditionally attributed to group interventions, such as vicar-
ious learning and social skills practice [34, 45], although
individual treatments are still preferred by patients [46].
Interestingly, what the present and the aforementioned
meta-analysis indicate is that individual and group inter-
ventions might lead to comparable benefits in FM pop-
ulations. In fact, it is possible that certain formats are more
adequate depending on patient characteristics than others
(e.g., patient personality). In our study, for example, some
patients showed acceptable changes after individual treat-
ment (e.g., patients 5 and 6), while patient 7 showed very
little change after treatment. A similar finding occurred with
group treatment (i.e., overall, the changes were larger for
patients 3 and 4 and smaller for patients 1 and 2). ,e
reduced number of individuals in the present investigation
prevents us from proposing any further conclusions in this
regard, but this raises interesting questions for future re-
search and for treatment personalization. While acknowl-
edging this, it is also important to note that group
interventions, if similarly effective, are often preferred by
institutions because they can be more cost-effective [47], so
efforts should be made to encourage patients to participate
in group interventions due to the limited resources in public
health settings [34].
As noted in the previous lines, not all patients responded
to the intervention to the same extent. ,e analysis of
predictors of response to treatment has been a topic of
interest to researchers in different health fields for decades
[48]. In chronic pain, however, research to date supports the
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idea that psychological treatment has a similar effect on
patient outcomes regardless of patient baseline character-
istics [49], even when the intervention is delivered online
[50]. A formal moderation analysis was not performed in the
present study due to the small number of participants and
the complexity of the data (a combination of all outcomes,
NAP indices, and baseline characteristics would be needed
in a formal analysis of moderators). Nevertheless, a visual
inspection of the data seems to support the aforementioned
idea that baseline clinical and demographic characteristics
do not moderate the response to psychological treatment.
For example, patients 5 and 6, who generally responded well
to the intervention, had somewhat different levels of pain
(5.6 and 3.7, respectively). Furthermore, pain levels were
similar in patients who had an acceptable response to the
treatment (3 to 6) and in patients who responded poorly to
the intervention (patients 1, 2, and 7). More research on
moderators of response to treatment is needed [51], for
example, by including psychological characteristics such as
fear-avoidance beliefs and pain catastrophizing [52, 53].
Still, in relation to the effectiveness of treatment, the
present investigation showed that ACT was less effective in
reducing pain severity compared to the remaining outcomes.
Research on FM has already indicated that changing pain
levels with psychological therapy is more challenging than
addressing other outcomes, such as depressive symptoms
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Post-session 5Post-session 4Post-session 3Post-session 2Post-session 1
NAP = 64%
Figure 1: Patient 3 evolution in sadness (moderate improvement). NAP: nonoverlap of all pairs.
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Post-session 5Post-session 4Post-session 3Post-session 2Post-session 1
NAP = 17%
Figure 2: Patient 2 evolution in fatigue (no improvement). NAP: nonoverlap of all pairs.
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and functional status [54–56]. According to ACT, a re-
duction in pain is not necessary to improve functioning [57].
,erefore, the present study findings indicating that out-
comes other than pain severity were improved to a greater
extent are consistent with ACT principles.
In addition to the exploration of treatment effectiveness,
an important study goal was to explore the feasibility of
implementing a new way of tracking patient response to
treatment, that is, EMA using a smartphone app. Overall, the
response rates suggest that the use of this new assessment
method is feasible, although app compliance was slightly
lower than that in similar studies [21]. However, it is im-
portant to note that the population in the present investi-
gation was older and less educated than that of the
previously mentioned study, which might have negatively
influenced the participants’ ability to comply with EMA
using technology. In fact, the participants were generally not
very familiar with the use of technology. Additional factors
that might also have contributed to lower response rates in
the present investigation are the duration of EMA, which
was two weeks longer in the present study, and the type of
pain in the populations, which was mostly back and neck
pain in the aforementioned investigation as opposed to
fibromyalgia in the present study. Indeed, the use of tech-
nology appears to be more challenging in the elderly [30].
However, as noted earlier in the present study, the use of
smartphone applications for patient monitoring has im-
portant advantages over traditional paper-and-pencil diaries
and episodic assessment, which helps understand why this
method has become the gold standard in health settings [58].
It is expected that, with the growing availability of smart-
phones and their widespread utilization globally and across
ages, we will see a reduction in technological barriers in the
elderly in the coming years [59].
Regarding app compliance, it is also important to note
that evening compliance was higher compared to morning
response rates. ,is is consistent with past findings [21] and
might be explained by the fact that sleep quality in this
population is frequently poor and often impacts on morning
functioning status [60]. While job status has been argued to
explain higher response rates in the evening (e.g., some
individuals working in the morning might have difficulties
in completing morning reports at work) [21], only one
participant in the present study was working during the
study. ,us, morning-to-evening differences in assessment
completion rates are not likely to be explained by job status.
Future research should take this into account maximizing
compliance with EMA in this population (i.e., by delaying
morning responses, which were planned to be at 10 am in the
present study, according to the patients’ preferred hours).
Strengths of the present investigation include the
implementation of a single-case design with several rep-
lications and the implementation of technology (i.e., a
smartphone app) for daily monitoring. Previous single-
case investigations in pain research have either used paper
diaries for daily assessment [43, 61], which are known to be
frequently completed retrospectively [62], or investigated
the impact of ACT on a single patient using two mea-
surement points only, that is, pretreatment and
posttreatment [63], which does not allow establishing a
reliable picture of patient baseline scores and change after
treatment. In fact, the study figures clearly proves the need
for ecological momentary assessment in an attempt to
obtain a more reliable measurement of outcomes in FM
patients, thus supporting the idea that ecological mo-
mentary assessment using technology is the gold standard
monitoring method in pain [64]. ,erefore, the present
investigation might provide researchers with a novel ap-
proach to exploring patient evolution and treatment ef-
fectiveness in pain settings as an alternative to episodic,
on-site assessment in large-scale randomized controlled
trials.
Despite the previous strengths, some study limitations
should also be considered. First, the study design was quasi-
experimental. While the reasons for not selecting more
complex, experimental SCDs have been already explained
(i.e., the comparison of group and individual treatment
would make multiple baselines complicated, and the
implementation of a psychological intervention would make
ABAB designs inadequate), this affects the internal validity
of findings (i.e., causality cannot be claimed). Additionally,
while replication was made for external validity, the number
of replications should be increased to allow for more
complex analyses (i.e., to explore whether a given format is
more effective for certain individuals or whether the extent
to which change occurs in a given patients can be related to
personal characteristics). ,ese are interesting lines of re-
search which might provide the reader with novel ideas for
future pain studies. Additionally, note that only 3 patients
were retained in the individual treatment condition, while
the best practice guidelines recommend 4 participants for
replication. Finally, the patient response rate was lower than
intended. While this provided sufficient information for our
analyses, the results are not ideal. It is possible that the
reasons are their low level of education, their poor experi-
ence with new technologies, and the technical problems
experienced with some old smartphones (i.e., low internal
memory in some moments which blocked the push system),
so our experience should serve similar studies to anticipate
these problems.
While acknowledging these limitations, the present
study might also have some important clinical and research
implications. First, it proved that a novel approach to pain
research, one that puts the focus on the patient as opposed to
average group scores, is possible. ,e pain literature on ACT
and other psychological interventions is clearly dominated
by randomized controlled trials which provide information
of average group response to treatment and evaluate out-
comes episodically [65, 66]. It is time to explore alternatives
to such designs, and the present study is a first step in this
direction.
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